ArticleOncotarget2015

Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS.

Barbie Taylor-Harding et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.